US Judge calls payments for patent settlements into question

Share this article:

Ed Silverman, writing in a Wall Street Journal blog post, claims that a recent US district court judge's opinion regarding patent settlements may call into question the very definition of "reverse settlements."

Teva, in trying to make a generic version of Lamictal—a drug used to treat epilepsy and bipolar disoder—was sued by GSK for patent infringement. The two drug makers settled the case with GSK allowing Teva to sell generic chewable and tablet forms of Lamictal before the drug's patent expired. 

In the federal court ruling that followed Judge William Walls wrote, "While there may be instances in which settlement without a monetary payment provision would raise antitrust concerns, this is not one," and suggested that since no money exchanged hands between GSK and Teva that the arrangement could not be scrutinized as anticompetitive.

Judge Walls also wrote in a case regarding patents for Pizer's statin Lipitor and AstraZeneca's acid reflux medicine Nexium that "other district courts have found that [the Supreme Court] ruling applies only to reverse settlements that involve money, this court...finds their readings unpersuasive."

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.